Biotek-snakken — Januar 2024
-
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
-
"The substantial increase from 2022 revenue of RMB12.8 million was mainly due to Xerava
's successful commercial launch in July 2023 and Nefecon's commercial launch in Macau in December 2023. This is also significantly higher than our previous 2023 revenue guidance of RMB70 to 100 million." -
"We will be launching Nefecon
soon in China, making this first-in-disease medicine available to 5 million IgAN patient in the country. We expect 2024 revenue to grow significantly from 2023, and would like to reaffirm our 2024 revenue guidance of RMB700 million." -
Top Picks: Two smaller adjustments before the earnings season
... Increasing in Calliditas (from 3.3% of the portfolio to 7%) ...
-
Lidt nyt fra Ascelia Pharma. 24 Jan. https://www.ascelia.com/mfn_news/orviglance-review-article-published-in-investigative-radiology/
-
Video - Steg 220% på kun 3 dage - og jeg har aktien (Evaxion)!
https://www.proinvestor.com/boards/118268 -
Calliditas: Vera Therapeutics has released interesting additional 2b results
-
"Exciting news as our new patent for TARPEYO now has been officially issued. This new patent, which provides protection until 2043, significantly strengthens TARPEYO’s product protection, further improving its unique value proposition. We are looking forward to continuing to expand our franchise IP protection in other territories."
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® - Calliditas Therapeutics AB | Renee Aguiar-Lucander
Exciting news as our new patent for TARPEYO now has been officially issued. This new patent, which provides protection until 2043, significantly strengthens TARPEYO’s product protection, further improving its unique value proposition. We are looking forward to continuing to expand our franchise IP protection in other territories. https://lnkd.in/dbqhAd_W
LinkedIn (www.linkedin.com)
-
-
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer – Alligator Bioscience
Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
(alligatorbioscience.se)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind